Sugi Predict

Sugi Predict / Compounds / SCHEMBL1015576

SCHEMBL1015576

SCHEMBL1015576

COc1cc2c(Cl)ncnc2cc1OCCCCl

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ENPP1 P22413 3/20 0.79
▸ EGFR P00533 8/20 0.47
▸ KDR P35968 6/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ FLT1 P17948 2/20 0.46
▸ HDAC3 O15379 2/20 0.46
▸ HDAC4 P56524 2/20 0.46
▸ HDAC1 Q13547 2/20 0.46
▸ HDAC7 Q8WUI4 2/20 0.46
▸ HDAC2 Q92769 2/20 0.46
▸ HDAC10 Q969S8 2/20 0.46
▸ HDAC11 Q96DB2 2/20 0.46
▸ HDAC8 Q9BY41 2/20 0.46
▸ HDAC6 Q9UBN7 2/20 0.46
▸ HDAC9 Q9UKV0 2/20 0.46
▸ HDAC5 Q9UQL6 2/20 0.46
▸ FGFR1 P11362 1/20 0.46
▸ FLT4 P35916 1/20 0.46
▸ SRC P12931 2/20 0.45
▸ PDE1B Q01064 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31620798 1.00 ENPP1 (0.79) ENPP1EGFRKDRMAPK1FLT1
SCHEMBL30864338 1.00 ENPP1 (0.79) ENPP1EGFRKDRMAPK1FLT1
SCHEMBL1013051 1.00 ENPP1 (0.79) ENPP1EGFRKDRMAPK1FLT1
Hydrochloric Acid SCHEMBL28825385 0.99 ENPP1 (0.77) ENPP1EGFRKDRMAPK1FLT1
SCHEMBL4029922 0.96 ENPP1 (0.77) ENPP1EGFRKDRMAPK1FLT1
SCHEMBL1013021 0.94 ENPP1 (0.79) ENPP1EGFRKDRMAPK1FLT1
SCHEMBL662795 0.94 ENPP1 (0.79) ENPP1EGFRKDRMAPK1FLT1
SCHEMBL1012358 0.94 ENPP1 (0.79) ENPP1EGFRKDRMAPK1FLT1
SCHEMBL8649615 0.90 ENPP1 (0.86) ENPP1EGFRKDRFLT1HDAC3
SCHEMBL16760503 0.90 ENPP1 (0.77) ENPP1EGFRKDRFLT1FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025073251-A1 COMPOUND CAPABLE OF DEGRADING EPIDERMAL GROWTH FACTOR RECEPTOR, AND USE THEREOF 普美瑞(苏州)生物科技有限公司 2025-04-10 — — WO disclosed
US-11713323-B2 Crystalline forms of therapeutic compounds and uses thereof KALA PHARMACEUTICALS, INC. (US) 2023-08-01 — — US disclosed
US-11713323-B2 Crystalline forms of therapeutic compounds and uses thereof KALA PHARMACEUTICALS, INC. (US) 2023-08-01 — — US disclosed
EP-2956138-B1 THERAPEUTIC COMPOUNDS AND USES THEREOF KALA PHARMACEUTICALS INC (US) 2022-06-22 — — EP disclosed
US-20210393641-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF OXFORD FINANCE LLC 2021-12-23 — — US disclosed
US-20210355133-A1 CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF KALA BIO, Inc. 2021-11-18 — — US disclosed
CN-106083836-B H based on quinazoline structure2S donor compound and application thereof 徐州医学院 2021-08-20 — — CN disclosed
US-10975090-B2 Crystalline forms of therapeutic compounds and uses thereof KALA PHARMACEUTICALS, INC. (US) 2021-04-13 — — US disclosed
US-10966987-B2 Therapeutic compounds and uses thereof KALA PHARMACEUTICALS, INC. (US) 2021-04-06 — — US disclosed
US-20200216459-A1 CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF KALA BIO, Inc. 2020-07-09 — — US disclosed
WO-2004087120-A2 USE OF QUINAZOLINE DERIVATIVES WITH SRC KINASE INHIBITORY ACTIVITY FOR THE TREATMENT OF HYPERTENSION ASTRAZENECA AB (SE) 2004-10-14 — — WO disclosed
EP-1463506-A1 SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF AURORA KINASES Astrazeneca AB (SE) 2004-10-06 — — EP disclosed
WO-2004081000-A1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2004-09-23 — — WO disclosed
WO-2004058782-A1 THERAPEUTIC QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2004-07-15 — — WO disclosed
WO-2004056812-A1 4- (PYRIDIN-4-YLAMINO) -QUINAZOLINE DERIVATIVES AS ANTI-TUMOR AGENTS ASTRAZENECA AB (SE) 2004-07-08 — — WO disclosed
WO-2004056801-A1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2004-07-08 — — WO disclosed
WO-2004043472-A1 COMBINATION PRODUCT OF INHIBITOR OF THE SRC FAMILY OF NON-RECEPTOR TYROSINE KINASES AND GEMCITABINE ASTRAZENECA AB (SE) 2004-05-27 — — WO disclosed
WO-2004041829-A1 QUINAZOLINE DERIVATIVES AS SRC TYROSINE KINASE INHIBITORS ASTRAZENECA AB (SE) 2004-05-21 — — WO disclosed
WO-2004004732-A1 QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2004-01-15 — — WO disclosed
WO-2003055491-A1 SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF AURORA KINASES ASTRAZENECA AB (SE) 2003-07-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11713323-B2 Crystalline forms of therapeutic compounds and uses thereof AQP3, CFTR, NPC1 ENPP1 1127/4885EGFR 3740/4885KDR 4668/4885
US-10966987-B2 Therapeutic compounds and uses thereof MUC1, CFTR, SLC26A4 ENPP1 2070/4885EGFR 829/4885KDR 4095/4885
US-20210355133-A1 CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF AQP3, CFTR, NPC1 ENPP1 1127/4885EGFR 3740/4885KDR 4668/4885
US-20210393641-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF MUC1, CFTR, SLC26A4 ENPP1 2070/4885EGFR 829/4885KDR 4095/4885
US-10975090-B2 Crystalline forms of therapeutic compounds and uses thereof AQP3, CFTR, NPC1 ENPP1 1127/4885EGFR 3740/4885KDR 4668/4885
US-20200216459-A1 CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF AQP3, CFTR, NPC1 ENPP1 1127/4885EGFR 3740/4885KDR 4668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.